MCID: GST030
MIFTS: 42

Gastrinoma malady

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrinoma

Aliases & Descriptions for Gastrinoma:

Name: Gastrinoma 12 52 42 14 69
Gastrin Secreting Tumor 12
Gastrinoma, Malignant 69
Malignant Gastrinoma 12
Gastrin Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5577
MeSH 42 D015408
NCIt 47 C3050
UMLS 69 C0017150

Summaries for Gastrinoma

Disease Ontology : 12 A neuroendocrine tumor that results_in an overproduction of gastric acid.

MalaCards based summary : Gastrinoma, also known as gastrin secreting tumor, is related to duodenal gastrinoma and pancreatic gastrinoma. An important gene associated with Gastrinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Signaling by GPCR and Gastric acid production. The drugs SecreFlo and Pantoprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, testes and small intestine, and related phenotype is endocrine/exocrine gland.

Wikipedia : 71 A gastrinoma is a tumor in the pancreas or duodenum that secretes excess of gastrin leading to... more...

Related Diseases for Gastrinoma

Diseases related to Gastrinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
id Related Disease Score Top Affiliating Genes
1 duodenal gastrinoma 12.0
2 pancreatic gastrinoma 12.0
3 gastric gastrinoma 11.9
4 zollinger-ellison syndrome 11.9
5 multiple endocrine neoplasia 1 10.8
6 duodenitis 10.4
7 multiple endocrine neoplasia 10.3
8 pancreatitis 10.3
9 post-vaccinal encephalitis 10.3 GAST SCT
10 hepatitis 10.3
11 autoimmune pancreatitis 10.2 CHGA GAST
12 gastric duplication cysts 10.2 CHGA GAST
13 syphilitic encephalitis 10.2 GAST SCT
14 granulocytopenia 10.2 CHGA GAST
15 nutritional optic neuropathy 10.2 GAST SST
16 cherubism 10.2 GAST SST
17 vein disease 10.2 GAST INS
18 adult ependymoblastoma 10.2 CHGA MEN1
19 acinar cell cystadenocarcinoma 10.2 CHGA GAST
20 myocardial stunning 10.2 GAST SST
21 pemphigus foliaceus 10.2 MEN1 SST
22 color blindness 10.2 GAST SST
23 diabetes mellitus, insulin-dependent, 2 10.2 INS SCT
24 uterine ligament cancer 10.2 MEN1 SST
25 dysgerminoma of ovary 10.2 CHGA MEN1
26 tooth erosion 10.2 SCT SST
27 early-onset parkinson disease 10.2 MEN1 SST
28 oculocutaneous albinism 10.1 CHGA SST
29 short bowel syndrome 10.1 SCT SST
30 breast secretory carcinoma 10.1 CHGA SST
31 cowper gland carcinoma 10.1 CHGA MEN1
32 childhood central nervous system mixed germ cell tumor 10.1 GAST SCT
33 pulmonary neuroendocrine tumor 10.1 MEN1 SST
34 adult botryoid rhabdomyosarcoma 10.1 CHGA SST
35 shaken baby syndrome 10.1 INS SST
36 neuroretinitis 10.1 MEN1 SST
37 brain ependymoma 10.1 INS SST
38 aneurysm 10.1 CHGA MEN1
39 growth retardation hydrocephaly lung hypoplasia 10.1 CHGA INS
40 breast malignant eccrine spiradenoma 10.1 GAST MEN1 SCT
41 protein s deficiency 10.1 INS SST
42 rheumatic encephalitis 10.1 MEN1 SST
43 photoparoxysmal response 3 10.1 INS SST
44 non-syndromic x-linked intellectual disability 10.1 CHGA SST
45 immune system organ benign neoplasm 10.1 MEN1 SST
46 bacterial gastritis 10.1 CHGA GAST SCT
47 gerstmann syndrome 10.1 CHGA INS
48 merkel cell carcinoma 10.1 INS SST
49 cowpox 10.1 CHGA GAST
50 tricuspid valve stenosis 10.1 GAST SCT SST

Graphical network of the top 20 diseases related to Gastrinoma:



Diseases related to Gastrinoma

Symptoms & Phenotypes for Gastrinoma

MGI Mouse Phenotypes related to Gastrinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.02 CHGA GAST INS MEN1 VIP

Drugs & Therapeutics for Gastrinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen Approved April 2002

Drugs for Gastrinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
2
Lansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3 3883
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
5 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
6
Dexlansoprazole Phase 4,Phase 1 138530-94-6, 103577-45-3 9578005
7
Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antacids Phase 4,Phase 3,Phase 2,Phase 1
10 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
11
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
12
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
13
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
14
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
15
Esomeprazole Approved, Investigational Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
19 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
20 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
22 Antimetabolites Phase 2, Phase 3,Phase 1
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
24 Analgesics Phase 3
25 Adjuvants, Anesthesia Phase 3
26 Cinacalcet Hydrochloride Phase 3
27 Narcotics Phase 3
28 Analgesics, Opioid Phase 3
29 Hormone Antagonists Phase 3,Phase 2,Phase 1
30 Anesthetics Phase 3
31 Hormones Phase 3,Phase 2,Phase 1
32 Anesthetics, General Phase 3
33 Anesthetics, Intravenous Phase 3
34 Peripheral Nervous System Agents Phase 3
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
36 Calcimimetic Agents Phase 3
37 Calcium, Dietary Phase 3,Phase 2,Phase 1
38 Central Nervous System Depressants Phase 3
39 Folate Nutraceutical Phase 2, Phase 3
40 Vitamin B9 Nutraceutical Phase 2, Phase 3
41 Cola Nutraceutical Phase 3,Phase 1
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
45
Omeprazole Approved, Investigational, Vet_approved Phase 2,Phase 1 73590-58-6 4594
46
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 54)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
3 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
5 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3
6 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3
7 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
9 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2
10 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2
11 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2
12 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
13 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
14 Effect of G17DT in Patients With Stage II/III Colorectal Cancer Completed NCT02518373 Phase 2
15 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
16 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
17 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2
18 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
19 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
20 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
21 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
22 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2
23 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2
24 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2
25 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2
26 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2
27 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
28 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2
29 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2
30 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2
31 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
32 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
33 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2
34 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
35 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
36 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
37 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
38 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
39 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
40 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
41 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Completed NCT00942175 Phase 1
42 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
43 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
44 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
45 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
46 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Unknown status NCT00730483
47 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
48 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
49 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
50 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240

Search NIH Clinical Center for Gastrinoma

Cochrane evidence based reviews: gastrinoma

Genetic Tests for Gastrinoma

Anatomical Context for Gastrinoma

MalaCards organs/tissues related to Gastrinoma:

39
Pancreas, Testes, Small Intestine, Lymph Node, Liver, Bone, Pancreatic Islet

Publications for Gastrinoma

Articles related to Gastrinoma:

(show top 50) (show all 419)
id Title Authors Year
1
Acute kidney injury following vomiting and diarrhea after endoscopy in a duodenal gastrinoma patient. ( 28070096 )
2017
2
(68)Ga-DOTATOC-PET/CT for effective diagnosis and treatment of pancreatic tail gastrinoma with multiple liver metastases: a case report. ( 26743558 )
2016
3
The Selective Arterial Calcium Injection Test is a Valid Diagnostic Method for Invisible Gastrinoma with Duodenal Ulcer Stenosis: A Case Report. ( 27348901 )
2016
4
Clinical treatment of gastrinoma: A case report and review of the literature. ( 27123130 )
2016
5
Sporadic, Primary Lymph Node Gastrinoma. ( 27457843 )
2016
6
Management of pancreatic gastrinoma associated with Von Hippel-Lindau disease: a case report. ( 27055912 )
2016
7
Metastatic gastrinoma in the breast mimicking primary solid papillary carcinoma. ( 27342908 )
2016
8
Synchronous Peripancreatic Lymph Node Gastrinoma and Gastric Neuroendocrine Tumor Type 2. ( 27209642 )
2016
9
Metastatic gastrinoma with secretory differentiation to ACTH. ( 27060354 )
2016
10
Diagnosis and preoperative tagging of duodenal gastrinoma by endoscopic ultrasound. ( 26492296 )
2015
11
Intraoperative near-infrared fluorescence visualization of theA duodenal gastrinoma in a patient withA Zollinger-Ellison syndrome. ( 26209566 )
2015
12
Surgery for gastrinoma: Short and long-term results. ( 25748044 )
2015
13
Impact of a novel 14a88bp MEN1 deletion in a patient with hyperparathyroidism and gastrinoma. ( 26191410 )
2015
14
Laparoscopic-assisted pancreaticoduodenectomy in a child with gastrinoma. ( 26711921 )
2015
15
Primary jejunal gastrinoma: a case report and review of the literature. ( 26546053 )
2015
16
Intraoperative Use of a Portable Large Field of View Gamma Camera and Handheld Gamma Detection Probe for Radioguided Localization and Prediction of Complete Surgical Resection of Gastrinoma: Proof of Concept. ( 26206636 )
2015
17
Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. ( 27408649 )
2015
18
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. ( 25625026 )
2015
19
Primary Hepatic Gastrinoma. ( 26556475 )
2015
20
Primary lymph node gastrinoma: 2 cases and a review of the literature. ( 25623161 )
2015
21
Metastatic gastrinoma in a pediatric patient with zollinger-ellison syndrome. ( 23426004 )
2014
22
Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. ( 25003221 )
2014
23
Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. ( 24961548 )
2014
24
Misdiagnosed gastrinoma: A case report. ( 24932294 )
2014
25
An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. ( 24796622 )
2014
26
An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: an unusual association and review of the literature. ( 25022420 )
2014
27
Primary lymph node gastrinoma. A diagnosis of exclusion. A case for duodenotomy in the setting of a negative imaging for primary tumor: A case report and review of the literature. ( 25462049 )
2014
28
Case of primary hepatic gastrinoma: Diagnostic usefulness of the selective arterial calcium injection test. ( 25145887 )
2014
29
Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 24431117 )
2013
30
Primary lymph node gastrinoma: a rare cause of abdominal pain in childhood. ( 23743959 )
2013
31
Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. ( 22743840 )
2013
32
Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. ( 22580937 )
2013
33
Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. ( 24363522 )
2013
34
Laparoscopic resection for primary lymph node gastrinoma. ( 23591435 )
2013
35
Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. ( 23417896 )
2013
36
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. ( 23613167 )
2013
37
Criteria for the glucagon provocative test in the diagnosis of gastrinoma. ( 22983734 )
2013
38
Primary hepatic gastrinoma causing zollinger-ellison syndrome: a rare and challenging diagnosis. ( 24213231 )
2012
39
Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. ( 23271988 )
2012
40
Images of the month: a gastrinoma in the uncinate process of the pancreas. ( 22764021 )
2012
41
Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1). ( 24213225 )
2012
42
Duodenal gastrinoma with multiple gastric neuroendocrine tumors secondary to chronic Helicobacter pylori gastritis. ( 22588069 )
2012
43
Impact of lymphadenectomy on survival in surgery for sporadic gastrinoma (Br J Surg 2012; 99: 1234-1240). ( 22864883 )
2012
44
Endobronchial metastasis from gastrinoma of the pancreas. ( 22383575 )
2012
45
Recurrence after surgical resection of gastrinoma: who, when, where and why? ( 22410712 )
2012
46
Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. ( 22864882 )
2012
47
Primary hepatic gastrinoma presenting as vague gastrointestinal symptoms. ( 22605007 )
2012
48
Visual vignette. Gastrinoma. ( 21940272 )
2012
49
Multiple giant duodenal ulcers associated with duodenal gastrinoma. ( 26181878 )
2012
50
Primary hepatic gastrinoma: Report of a case and review of literature. ( 21607163 )
2011

Variations for Gastrinoma

Cosmic variations for Gastrinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM532 KRAS small intestine,duodenum,adenoma,intestinal c.38G>A p.G13D 3
2 COSM521 KRAS small intestine,duodenum,adenoma,intestinal c.35G>A p.G12D 3

Expression for Gastrinoma

Search GEO for disease gene expression data for Gastrinoma.

Pathways for Gastrinoma

Pathways related to Gastrinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 GAST INS MEN1 NMB SCT SST
2 9.64 GAST SCT VIP

GO Terms for Gastrinoma

Cellular components related to Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA GAST INS SCT SST
2 extracellular region GO:0005576 9.17 CHGA GAST INS NMB SCT SST

Biological processes related to Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.56 GAST INS SST VIP
2 regulation of protein localization GO:0032880 9.16 INS VIP
3 cell-cell signaling GO:0007267 9.13 INS NMB SST
4 negative regulation of vasodilation GO:0045908 8.62 CHGA INS

Molecular functions related to Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 GAST INS NMB SCT SST VIP

Sources for Gastrinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....